हमारे बारे में
HCPs
New Page
मरीजों की कहानियां
संलग्न मिल
घर
Who we are
What we do
Events
प्रारंभिक निदान
NICE
वीडियो
Copy of Reports
साधन
दुकान
संपर्क करें
Menu
Brigatinib is a 2nd generation TKI developed by Takeda. The recommended dose is 180mg taken daily. Along with Alectinib, Brigatinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients